Published in final edited form as:

Pediatr Nephrol. 2014 April ; 29(4): 505–511. doi:10.1007/s00467-013-2548-y.

Polycystin-1 Cleavage and the Regulation of Transcriptional Pathways

David Merrick, Claudia A. Bertuccio, Hannah C. Chapin, Mark Lal, Veronique Chauvet, and Michael J. Caplan

Department of Cellular and Molecular Physiology, Yale University School of Medicine

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic cause of end stage renal disease, affecting ~1 in 1,000 people. The disease is characterized by the development of numerous large fluid filled renal cysts over the course of decades. These cysts compress the surrounding renal parenchyma and impair its function. Mutations in two genes are responsible for ADPKD. The protein products of both of these genes, polycystin-1 and polycystin-2, localize to the primary cilium and participate in a wide variety of signaling pathways. Polycystin-1 undergoes several proteolytic cleavages that produce fragments that manifest biological activities. Recent results suggest that the production of polycystin-1 cleavage fragments is necessary and sufficient to account for at least some, although certainly not all, of the physiological functions of the parent protein.

Keywords

Autosomal dominant polycystic kidney disease; transcription; proliferation; apoptosis; Wnt; CHOP; proteolytic cleavage

Molecular pathogenesis of autosomal dominant polycystic kidney disease

Autosomal Dominant Polycystic Kidney Disease (ADPKD) affects ~1 in 1,000 people and is the most common potentially lethal genetic disease [1–3]. ADPKD is marked by massive enlargement of the kidneys that is attributable to an abundance of large, fluid-filled cysts. These cysts develop over the span of decades and their expansion destroys adjacent renal parenchyma, leading to end-stage renal disease in ~50% of cases. ADPKD is also associated with cardiovascular, musculoskeletal, and gastrointestinal abnormalities [4]. ADPKD is caused by mutations in the *PKD1* and *PKD2* genes that encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively. Most ADPKD cases (~85%) are due to mutations in *PKD1*, while mutations in *PKD2* account for almost all of the remaining cases.

A great deal of effort has been focused on elucidating the mechanisms responsible for the autosomal pattern of inheritance in ADPKD. Elegant studies of the genetic material associated with individual cysts suggest that loss of heterozygosity may account for a substantial fraction of cyst development [5]. According to this scenario, cysts arise when “second hit” somatic mutations occur in individual renal epithelial cells that carry one germ line mutant *PKD1* or *PKD2* allele. Cells that lose their wild type copies of *PKD1* or *PKD2* go on to manifest the hyper-proliferative and secretory phenotypes that characterize the cyst lining epithelial cells. In this case, each cyst can be thought of as essentially a benign tumor

and the *PKD1* and *PKD2* genes can be seen to function as benign tumor suppressors. A second model posits that individual cysts may arise as a consequence stressful stimuli in the context of *PKD1* or *PKD2* haploinsufficiency. The reduced levels of PC1 or PC2 expression associated with heterozygosity might predispose renal epithelial cells to respond to conditions of stress, such as those associated with renal injury, by manifesting the cystic phenotype [6, 7]. These models are not mutually exclusive and both of them can account for the slow acquisition of cysts over the space of many years that characterizes the natural history of ADPKD.

Polycystin-1 and 2 structure, function and localization

PC1 is an extremely large protein, with a mass exceeding 460 kDa and 11 predicted transmembrane spans [8, 9]. PC1 is predicted to possess a large (~3,000 amino acid) extracellular N terminal domain and a short (~200 amino acid) C terminal domain that faces the cytoplasm. The massive PC1 extracellular N terminal domain includes 16 copies of an Ig-like sequence known as the polycystin repeat. It also embodies a number of interesting molecular motifs [10–12] that can participate in protein-protein interactions, supporting the suggestion that PC1 may participate in cell-cell or cell-matrix associations [12–16]. The extracellular domains of PC1 and PC2 may also sense fluid flow and pressure in the kidney [17]. Relatives of PC1 and 2 (PC1L3 and PC2L1) respond to acidic pH and may contribute to sour taste detection by the tongue [18–20], suggesting that PC1 and 2 may similarly possess chemosensory properties. PC1 is implicated in a variety of pathways tied to proliferation, including G-protein signaling and the Wnt, AP-1, NFAT [21] and JAK-STAT cascades [22–28]. Moreover, depletion of PC1 increases the rate of cell growth while its overexpression slows cell this process, indicating that PC1 may negatively regulate proliferation [29, 30].

PC2 has a MW of ~110 kDa and 6 putative membrane spanning regions [31, 32]. PC2 is a Ca^{2+} permeable cation channel belonging to the transient receptor potential (TRP) family [33, 34]. PC2 mediates the release of Ca^{2+} from intracellular stores and transduces mechanostimulatory signals from the primary cilium [35]. The C terminal cytoplasmic tail of PC1 contains a coiled coil domain that mediates its interaction with PC2 [36, 37]. PC1 and PC2 associate with one another in renal epithelial cells, but little is known about what regulates that association [38]. PC2 may be involved in several signaling pathways [39, 40], including some of the same growth-suppression pathways that have been attributed to PC1 [27]. The PC1 and PC2 proteins interact physically with one another and with numerous other proteins that may modulate their trafficking properties or their involvement in signal transduction [41].

Subsets of the populations of the PC1 and PC2 proteins are associated with the primary cilium [42, 43], where they appear to participate in mechanosensory or chemosensory processes. PC1 and PC2 may also be shed in exosome-like vesicles that can interact with the primary cilium [44]. ADPKD is the most prevalent member of the “ciliopathies”, which is a recently-defined class of genetic disorders that result from mutations in genes that encode proteins associated with cilium or the basal body [45]. While these disorders are characterized by a variety of pathologies, many of them are notable for the presence of renal cysts [46]. To elucidate the pathogenesis of ADPKD, as well as to understand the function of PC1 and PC2, it will be necessary to develop a thorough insight into these proteins’ roles in the primary cilium and of the mechanisms that control their association with this intriguing organelle.

Polycystin-1 cleavage

PC1 is cleaved at sites in both its N- and C-terminal domains [47]. The N-terminal cleavage takes place at the G protein-coupled receptor proteolytic site (GPS), close to the beginning of the first transmembrane domain [48]. This *cis*-autoproteolytic cleavage occurs as PC1 traverses the secretory pathway [48] and is stimulated by PC2 [49]. The cleaved N-terminus appears to remain non-covalently attached to the membrane-bound C-terminal fragment [50]. Mutant forms of PC1 that cannot undergo GPS cleavage are not able to rescue the PKD phenotype in *PKDI*^{-/-} mice [51]. More importantly, a comparable missense mutation is sufficient to cause human ADPKD [48, 51, 52]. A PC1 mutant that cannot undergo GPS cleavage does not reach the cell surface [49].

At least 3 other cleavages liberate portions of the cytoplasmic C-terminal tail (CTT) of PC1 (Fig. 1). One of these cleavages releases a ~35 kDa soluble portion of the tail that accumulates in the nucleus in response to decreased fluid flow in the murine kidney [53, 54]. Low et al. found a more distal cleavage that releases a 17 kDa fragment that interacts with the transcriptional activators STAT3 and STAT6 and the co-activator p100 [28, 55]. Flow cessation increased this cleavage as well as the nuclear translocation of both the PC1 tail [53] and STAT6 [28, 55]. A fragment with 6 transmembrane domains that regulates store-operated calcium entry [47] has also been identified. Although the sizes of these 3 fragments have been determined and their production is apparently regulated, the amino acid sequences of their cleavage sites, and the enzymes and signals that selectively activate each cleavage process have yet to be determined. The C-terminal tail of PC1 contains a PEST sequence, which may facilitate its ubiquitin-mediated degradation [55, 56].

These observations suggest the existence of novel signaling pathways in which CTT fragments of PC1 carry messages from the cell surface to the nucleus. Nuclear translocation of PC1 CTT fragments raises a series of obvious but nonetheless fascinating questions, namely: “What are the PC1 CTT fragments doing there? Whom do they talk to and what do they say?”. Recent studies indicate that nuclear CTT interacts with transcription factors and proteins that modulate gene expression. These studies illuminate a new pathway through which the PC1 CTT influences the activities of several transcription factors whose targets have been linked with PC1 function [57]. It is important to stress, however, that cleavage is one of many physiological processes in which PC1 appears to participate. Cleavage certainly does not account for all of PC1’s functional properties, and cleavage-independent PC1 activities are without doubt critically important aspects of the PC1 protein’s biology.

To characterize fully the proteolytic events that release PC1 CTT fragments, it will be necessary to ascertain whether and how these cleavages are predicated upon one another [47, 48, 50, 55], to determine which enzymes are responsible, and to establish these enzymes’ sites of action within the PC1 protein. Recent data indicate that γ -secretase plays an obligate role in releasing the 35 kDa PC1 CTT and that the phenotype of wild type cultured renal epithelial cells subjected to γ -secretase inhibition resembles that of *PKDI*^{-/-} cells [57].

Polycystin-1 cleavage and the regulation of the Wnt pathway

Proliferation and apoptosis are prominent among the many cellular processes that are perturbed when expression of the polycystin proteins is disrupted [2, 41]. Cyst-lining epithelial cells appear to be hyper-proliferative [1] and, at least in some models, to manifest high rates of apoptosis [58]. A number of pro-proliferative pathways appear to be activated in the cells that line ADPKD cysts. A gene expression analysis performed on human

ADPKD cyst epithelial cells revealed that a number of targets of the Wnt signaling pathway are up-regulated in this tissue [59].

The Wnt signaling cascade controls the quantity and activity of β -catenin [60], which is a soluble cytoplasmic polypeptide that interacts with adhesion molecules at sites of cell-cell contact and helps to nucleate the assembly of the sub-membranous cytoskeleton. When β -catenin is released from cell adhesion complexes it can enter the nucleus, where it binds to and activates the T-cell factor (TCF) transcription factor, which in turn directs the expression of genes whose products drive proliferation. Prior to reaching the nucleus, β -catenin can be recognized by a “destruction complex” that phosphorylates it and targets it for degradation in the proteasome. The binding of extracellular Wnt proteins to their plasma membrane receptor leads to the inactivation of the destruction complex and allows β -catenin to co-activate pro-proliferative pathways. Like many transcription factors, TCF depends upon an interaction with the transcriptional co-activator p300 in order to mediate the transcription of its target genes [61]. The ~35 kDa PC1-CTT fragment binds to TCF and prevents it from interacting with p300 [57]. Thus, this PC1 cleavage product acts a profound inhibitor of TCF-mediated gene expression. At least some component of the anti-proliferative influence of PC1 expression, therefore, may be attributable to the ability of a PC1 C terminal tail fragment to suppress the downstream effectors of the Wnt signaling pathway.

Polycystin-1 cleavage and the regulation of the C/EBP homologous protein (CHOP) pathway

A high throughput screen has been performed to identify additional transcription factors whose functions might be modulated by PC1 CTT fragments [57]. This effort revealed that activity the CHOP transcription factor is inhibited by the expression of a construct whose sequence corresponds to the C terminal 200 amino acid residues of the PC1 protein. CHOP (also known as Ddit3 and GADD153) is involved in the propagation of apoptosis in response to endoplasmic reticulum stress [62, 63] that occurs upon accumulation of unfolded or mis-folded proteins [64]. The initial cellular responses to ER stress involve efforts to reduce the incoming load of proteins into the ER [65], to up-regulate the expression of chaperones to assist in protein folding and to eject mis-folded proteins from the endoplasmic reticulum for destruction by the ubiquitin-proteasome system [66, 67]. If these measures are not sufficient to clear unfolded proteins from the endoplasmic reticulum, the cell commits to apoptosis [68]. Three signaling pathways are employed in the initiation of apoptosis: transcriptional activation of CHOP, activation of the JNK pathway by Ire1-TNF/ASK1 complex [68], and activation of ER-associated caspase-12 [69].

CHOP is a 29 kDa protein containing an N-terminal transcriptional activation domain and a C-terminal basic-leucine zipper (bZIP) domain, which is essential for CHOP-induced apoptosis [63, 70]. Under normal physiological conditions, CHOP is ubiquitously expressed at very low levels, but its expression is highly up-regulated upon induction of endoplasmic reticulum stress [71]. While much progress has been made in elucidating the signaling pathways that regulate CHOP activation, relatively little is known about the downstream targets of CHOP. Over-expression of CHOP leads to cell cycle arrest and apoptosis [63, 72], whereas CHOP^{-/-} mice demonstrate reduced cellular apoptosis in response to endoplasmic reticulum stress [73].

Like TCF, CHOP requires an interaction with the p300 transcriptional co-activator in order to function [61, 74]. The ~35 kDa fragment of PC1 binds to CHOP and prevents it from assembling with p300 [57]. In keeping with this behavior, over-expression of a construct that corresponds to the ~35 kDa C terminal tail fragment of PC1 reduces CHOP activity, as

measured by transcriptional reporter assays. More significantly, overexpression of this PC1-CTT fragment also dramatically reduces the high rate of apoptosis that is observed in *Pkd1*^{-/-} cells grown in culture. Thus, PC1 fragments produced as a consequence of PC1 cleavage appear to interact with and suppress the activities of pro-proliferative and pro-apoptotic transcription factors through very similar mechanisms (see Figure 2).

Signaling by PC1 cleavage fragments *in vivo*

The *in vitro* experiments discussed in the preceding sections suggest that C terminal tail fragments of the PC1 protein possess biological activity and that they are able to influence transcriptional pathways that are relevant to aspects of the ADPKD phenotype. Confirmation of the relevance of PC1 C terminal cleavage to the prevention or development of ADPKD, however, will require demonstrations that these processes are necessary and sufficient to account for at least some of the functions of the PC1 protein *in vivo*.

Zebrafish express two *Pkd1* orthologues, *Pkd1a* and *Pkd1b*. The simultaneous morpholino-induced knockdown of *Pkd1a* and *Pkd1b* expression in zebrafish embryos produces a number of phenotypes, including pronephric duct cysts, hydrocephalus and skeletal abnormalities [75]. One of the most robust and readily quantifiable of these phenotypes is the development of upward-facing tail curvature. It is interesting to note that a similar tail curvature is also observed in zebrafish embryos that have been treated with inhibitors of γ -secretase [76]. While the γ -secretase-dependent pathway that is responsible for this effect has not been fully elucidated, its similarity to the *Pkd1a* and *Pkd1b* morphant phenotype suggests that these two interventions may influence the same process. Support for this hypothesis derives from the observation that transgenic expression of a construct encoding the C terminal 200 amino acid residues of PC1 is sufficient to at least partially rescue the tail curvature phenotypes that are produced by both *Pkd1a* and *Pkd1b* knockdown and by γ -secretase inhibition [57]. These data lend *in vivo* support to the concept that PC1 C terminal tail cleavage is required in order for this protein to fulfill its biological functions and that a released fragment of the PC1 C terminal tail is sufficient to recapitulate at least some of those functions.

Conclusions

ADPKD is a complex disease. Its pathogenesis is attributable to mutations in two genes whose products localize to a number of cellular structures and participate in a number of cellular signaling pathways. Both polycystin-1 and polycystin-2 localize to the primary cilium, and this fascinating organelle clearly plays a critical role in governing processes that, when perturbed, participate in the development of renal cysts. Much remains to be learned about the nature of these processes and about the cellular machinery through which they are actuated. The polycystin-1 protein undergoes several proteolytic cleavages, and the products of these cleavages possess important biological activities. The production of at least some of these fragments appears to be a prerequisite in order for polycystin-1 to fulfill its complete range of physiological functions. Furthermore, these fragments appear to be capable of mediating some of these functions even when expression of the full length parent protein is suppressed or absent. Future research will be required to understand how and where polycystin-1 is cleaved, and to determine whether and how these cleavages are obligate aspects of the biology of the polycystins and polycystic kidney disease.

Acknowledgments

The authors wish to thank all of the members of the Caplan laboratory past and present for helpful discussions and valuable input. Work from the authors' laboratory that was discussed in this review was supported by Department

of Defense Peer Reviewed Medical Research Program grant number W81XWH-10-1-0504 and by NIH grant P30 DK090744.

References

1. Calvet JP, Grantham JJ. The genetics and physiology of polycystic kidney disease. *Semin Nephrol.* 2001; 21:107–123. [PubMed: 11245774]
2. Takiar V, Caplan MJ. Polycystic kidney disease: Pathogenesis and potential therapies. *Biochim Biophys Acta.* 2010
3. Harris PC, Torres VE. Polycystic kidney disease. *Annu Rev Med.* 2009; 60:321–337. [PubMed: 18947299]
4. Gabow PA. Autosomal dominant polycystic kidney disease. *N Engl J Med.* 1993; 329:332–342. [PubMed: 8321262]
5. Qian F, Watnick TJ, Onuchic LF, Germino GG. The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. *Cell.* 1996; 87:979–987. [PubMed: 8978603]
6. Bastos AP, Piontek K, Silva AM, Martini D, Menezes LF, Fonseca JM, Fonseca II, Germino GG, Onuchic LF. Pkd1 haploinsufficiency increases renal damage and induces microcyst formation following ischemia/reperfusion. *J Am Soc Nephrol.* 2009; 20:2389–2402. [PubMed: 19833899]
7. Takakura A, Contrino L, Zhou X, Bonventre JV, Sun Y, Humphreys BD, Zhou J. Renal injury is a third hit promoting rapid development of adult polycystic kidney disease. *Hum Mol Genet.* 2009; 18:2523–2531. [PubMed: 19342421]
8. Harris PC, Germino G, Klinger K, Landes G, van Adelsberg J. The PKD1 gene product. *Nat Med.* 1995; 1:493. [PubMed: 7585106]
9. Nims N, Vassmer D, Maser RL. Transmembrane domain analysis of polycystin-1, the product of the polycystic kidney disease-1 (PKD1) gene: evidence for 11 membrane-spanning domains. *Biochemistry.* 2003; 42:13035–13048. [PubMed: 14596619]
10. Hughes J, Ward CJ, Peral B, Aspinwall R, Clark K, San Millan JL, Gamble V, Harris PC. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. *Nat Genet.* 1995; 10:151–160. [PubMed: 7663510]
11. Lohning C, Pohlschmidt M, Glucksmann-Kuis MA, Duyk G, Bork P, Schneider MO, Reeders ST, Frischauf AM. Structural motifs of the PKD1 protein. *Nephrol Dial Transplant.* 1996; 11(Suppl 6): 2–4. [PubMed: 9044318]
12. Ibraghimov-Beskrovnaya O, Bukanov NO, Donohue LC, Dackowski WR, Klinger KW, Landes GM. Strong homophilic interactions of the Ig-like domains of polycystin-1, the protein product of an autosomal dominant polycystic kidney disease gene, PKD1. *Hum Mol Genet.* 2000; 9:1641–1649. [PubMed: 10861291]
13. Streets AJ, Newby LJ, O'Hare MJ, Bukanov NO, Ibraghimov-Beskrovnaya O, Ong AC. Functional analysis of PKD1 transgenic lines reveals a direct role for polycystin-1 in mediating cell-cell adhesion. *J Am Soc Nephrol.* 2003; 14:1804–1815. [PubMed: 12819240]
14. Streets AJ, Wagner BE, Harris PC, Ward CJ, Ong AC. Homophilic and heterophilic polycystin 1 interactions regulate E-cadherin recruitment and junction assembly in MDCK cells. *J Cell Sci.* 2009; 122:1410–1417. [PubMed: 19351715]
15. Babich V, Zeng WZ, Yeh BI, Ibraghimov-Beskrovnaya O, Cai Y, Somlo S, Huang CL. The N-terminal extracellular domain is required for polycystin-1-dependent channel activity. *J Biol Chem.* 2004; 279:25582–25589. [PubMed: 15060061]
16. van Adelsberg J. Peptides from the PKD repeats of polycystin, the PKD1 gene product, modulate pattern formation in the developing kidney. *Dev Genet.* 1999; 24:299–308. [PubMed: 10322638]
17. Patel A, Honore E. Polycystins and renovascular mechanosensory transduction. *Nat Rev Nephrol.* 2010
18. Huang AL, Chen X, Hoon MA, Chandrashekar J, Guo W, Trankner D, Ryba NJ, Zuker CS. The cells and logic for mammalian sour taste detection. *Nature.* 2006; 442:934–938. [PubMed: 16929298]

19. Kawaguchi H, Yamanaka A, Uchida K, Shibasaki K, Sokabe T, Maruyama Y, Yanagawa Y, Murakami S, Tominaga M. Activation of polycystic kidney disease-2-like 1 (PKD2L1)-PKD1L3 complex by acid in mouse taste cells. *J Biol Chem.* 2010; 285:17277–17281. [PubMed: 20406802]
20. Ishimaru Y, Inada H, Kubota M, Zhuang H, Tominaga M, Matsunami H. Transient receptor potential family members PKD1L3 and PKD2L1 form a candidate sour taste receptor. *Proc Natl Acad Sci U S A.* 2006; 103:12569–12574. [PubMed: 16891422]
21. Puri S, Magenheimer BS, Maser RL, Ryan EM, Zien CA, Walker DD, Wallace DP, Hempson SJ, Calvet JP. Polycystin-1 activates the calcineurin/NFAT (nuclear factor of activated T-cells) signaling pathway. *J Biol Chem.* 2004; 279:55455–55464. [PubMed: 15466861]
22. Kim E, Arnould T, Sellin LK, Benzing T, Fan MJ, Gruning W, Sokol SY, Drummond I, Walz G. The polycystic kidney disease 1 gene product modulates Wnt signaling. *J Biol Chem.* 1999; 274:4947–4953. [PubMed: 9988738]
23. Le NH, van der Bent P, Huls G, van de Wetering M, Loghman-Adham M, Ong AC, Calvet JP, Clevers H, Breuning MH, van Dam H, Peters DJ. Aberrant polycystin-1 expression results in modification of activator protein-1 activity, whereas Wnt signaling remains unaffected. *J Biol Chem.* 2004; 279:27472–27481. [PubMed: 15087466]
24. Parnell SC, Magenheimer BS, Maser RL, Zien CA, Frischauf AM, Calvet JP. Polycystin-1 activation of c-Jun N-terminal kinase and AP-1 is mediated by heterotrimeric G proteins. *J Biol Chem.* 2002; 277:19566–19572. [PubMed: 11912216]
25. Kim E, Arnould T, Sellin L, Benzing T, Comella N, Kocher O, Tsiokas L, Sukhatme VP, Walz G. Interaction between RGS7 and polycystin. *Proc Natl Acad Sci U S A.* 1999; 96:6371–6376. [PubMed: 10339594]
26. Arnould T, Kim E, Tsiokas L, Jochimsen F, Gruning W, Chang JD, Walz G. The polycystic kidney disease 1 gene product mediates protein kinase C alpha-dependent and c-Jun N-terminal kinase-dependent activation of the transcription factor AP-1. *J Biol Chem.* 1998; 273:6013–6018. [PubMed: 9497315]
27. Bhunia AK, Piontek K, Boletta A, Liu L, Qian F, Xu PN, Germino FJ, Germino GG. PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. *Cell.* 2002; 109:157–168. [PubMed: 12007403]
28. Talbot JJ, Shillingford JM, Vasanth S, Doerr N, Mukherjee S, Kinter MT, Watnick T, Weimbs T. Polycystin-1 regulates STAT activity by a dual mechanism. *Proc Natl Acad Sci U S A.* 2011; 108:7985–7990. [PubMed: 21518865]
29. Boletta A, Qian F, Onuchic LF, Bhunia AK, Phakdeekitcharoen B, Hanaoka K, Guggino W, Monaco L, Germino GG. Polycystin-1, the gene product of PKD1, induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells. *Mol Cell.* 2000; 6:1267–1273. [PubMed: 11106764]
30. Sutters M, Yamaguchi T, Maser RL, Magenheimer BS, St John PL, Abrahamson DR, Grantham JJ, Calvet JP. Polycystin-1 transforms the cAMP growth-responsive phenotype of M-1 cells. *Kidney Int.* 2001; 60:484–494. [PubMed: 11473631]
31. Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, Reynolds DM, Cai Y, Gabow PA, Pierides A, Kimberling WJ, Breuning MH, Deltas CC, Peters DJ, Somlo S. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. *Science.* 1996; 272:1339–1342. [PubMed: 8650545]
32. Cai Y, Maeda Y, Cedzich A, Torres VE, Wu G, Hayashi T, Mochizuki T, Park JH, Witzgall R, Somlo S. Identification and characterization of polycystin-2, the PKD2 gene product. *J Biol Chem.* 1999; 274:28557–28565. [PubMed: 10497221]
33. Gonzalez-Perrett S, Kim K, Ibarra C, Damiano AE, Zotta E, Batelli M, Harris PC, Reisin IL, Arnaout MA, Cantiello HF. Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca²⁺-permeable nonselective cation channel. *Proceedings of the National Academy of Sciences of the United States of America.* 2001; 98:1182–1187. [PubMed: 11252306]
34. Tsiokas L, Arnould T, Zhu C, Kim E, Walz G, Sukhatme VP. Specific association of the gene product of PKD2 with the TRPC1 channel. *Proc Natl Acad Sci U S A.* 1999; 96:3934–3939. [PubMed: 10097141]

35. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, Elia AE, Lu W, Brown EM, Quinn SJ, Ingber DE, Zhou J. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. *Nat Genet.* 2003; 33:129–137. [PubMed: 12514735]
36. Qian F, Germino FJ, Cai Y, Zhang X, Somlo S, Germino GG. PKD1 interacts with PKD2 through a probable coiled-coil domain. *Nat Genet.* 1997; 16:179–183. [PubMed: 9171830]
37. Tsiokas L, Kim E, Arnould T, Sukhatme VP, Walz G. Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2. *Proc Natl Acad Sci U S A.* 1997; 94:6965–6970. [PubMed: 9192675]
38. Newby LJ, Streets AJ, Zhao Y, Harris PC, Ward CJ, Ong AC. Identification, characterization, and localization of a novel kidney polycystin-1-polycystin-2 complex. *J Biol Chem.* 2002; 277:20763–20773. [PubMed: 11901144]
39. Delmas P, Nomura H, Li X, Lakkis M, Luo Y, Segal Y, Fernandez-Fernandez JM, Harris P, Frischauf AM, Brown DA, Zhou J. Constitutive activation of G-proteins by polycystin-1 is antagonized by polycystin-2. *J Biol Chem.* 2002; 277:11276–11283. [PubMed: 11786542]
40. Arnould T, Sellin L, Benzing T, Tsiokas L, Cohen HT, Kim E, Walz G. Cellular activation triggered by the autosomal dominant polycystic kidney disease gene product PKD2. *Mol Cell Biol.* 1999; 19:3423–3434. [PubMed: 10207066]
41. Chapin HC, Caplan MJ. The cell biology of polycystic kidney disease. *J Cell Biol.* 2010; 191:701–710. [PubMed: 21079243]
42. Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. *J Am Soc Nephrol.* 2002; 13:2508–2516. [PubMed: 12239239]
43. Pazour GJ, Witman GB. The vertebrate primary cilium is a sensory organelle. *Curr Opin Cell Biol.* 2003; 15:105–110. [PubMed: 12517711]
44. Hogan MC, Manganelli L, Woollard JR, Masyuk AI, Masyuk TV, Tammachote R, Huang BQ, Leontovich AA, Beito TG, Madden BJ, Charlesworth MC, Torres VE, LaRusso NF, Harris PC, Ward CJ. Characterization of PKD protein-positive exosome-like vesicles. *J Am Soc Nephrol.* 2009; 20:278–288. [PubMed: 19158352]
45. Tobin JL, Beales PL. The nonmotile ciliopathies. *Genet Med.* 2009; 11:386–402. [PubMed: 19421068]
46. Badano JL, Mitsuma N, Beales PL, Katsanis N. The ciliopathies: an emerging class of human genetic disorders. *Annu Rev Genomics Hum Genet.* 2006; 7:125–148. [PubMed: 16722803]
47. Woodward OM, Li Y, Yu S, Greenwell P, Wodarczyk C, Boletta A, Guggino WB, Qian F. Identification of a polycystin-1 cleavage product, P100, that regulates store operated Ca entry through interactions with STIM1. *PLoS One.* 2010; 5:e12305. [PubMed: 20808796]
48. Qian F, Boletta A, Bhunia AK, Xu H, Liu L, Ahrabi AK, Watnick TJ, Zhou F, Germino GG. Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations. *Proc Natl Acad Sci U S A.* 2002; 99:16981–16986. [PubMed: 12482949]
49. Chapin HC, Rajendran V, Caplan MJ. Polycystin-1 Surface Localization Is Stimulated by Polycystin-2 and Cleavage at the G Protein-coupled Receptor Proteolytic Site. *Mol Biol Cell.* 2010; 21:4338–4348. [PubMed: 20980620]
50. Wei W, Hackmann K, Xu H, Germino G, Qian F. Characterization of cis-autoproteolysis of polycystin-1, the product of human polycystic kidney disease 1 gene. *J Biol Chem.* 2007; 282:21729–21737. [PubMed: 17525154]
51. Yu S, Hackmann K, Gao J, He X, Piontek K, Garcia-Gonzalez MA, Menezes LF, Xu H, Germino GG, Zuo J, Qian F. Essential role of cleavage of Polycystin-1 at G protein-coupled receptor proteolytic site for kidney tubular structure. *Proc Natl Acad Sci U S A.* 2007; 104:18688–18693. [PubMed: 18003909]
52. Xu C, Rossetti S, Jiang L, Harris PC, Brown-Glaberman U, Wandinger-Ness A, Bacallao R, Alper SL. Human ADPKD primary cyst epithelial cells with a novel, single codon deletion in the PKD1 gene exhibit defective ciliary polycystin localization and loss of flow-induced Ca²⁺ signaling. *Am J Physiol Renal Physiol.* 2007; 292:F930–F945. [PubMed: 17090781]

53. Chauvet V, Tian X, Husson H, Grimm DH, Wang T, Hiesberger T, Igarashi P, Bennett AM, Ibraghimov-Beskrovnaya O, Somlo S, Caplan MJ. Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. *J Clin Invest*. 2004; 114:1433–1443. [PubMed: 15545994]
54. Bertuccio CA, Chapin HC, Cai Y, Mistry K, Chauvet V, Somlo S, Caplan MJ. Polycystin-1 C-terminal cleavage is modulated by polycystin-2 expression. *J Biol Chem*. 2009; 284:21011–21026. [PubMed: 19491093]
55. Low SH, Vasanth S, Larson CH, Mukherjee S, Sharma N, Kinter MT, Kane ME, Obara T, Weimbs T. Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. *Dev Cell*. 2006; 10:57–69. [PubMed: 16399078]
56. Rechsteiner M, Rogers SW. PEST sequences and regulation by proteolysis. *Trends Biochem Sci*. 1996; 21:267–271. [PubMed: 8755249]
57. Merrick D, Chapin H, Baggs JE, Yu Z, Somlo S, Sun Z, Hogenesch JB, Caplan MJ. The gamma-Secretase Cleavage Product of Polycystin-1 Regulates TCF and CHOP-Mediated Transcriptional Activation through a p300-Dependent Mechanism. *Dev Cell*. 2012; 22:197–210. [PubMed: 22178500]
58. Goilav B. Apoptosis in polycystic kidney disease. *Biochim Biophys Acta*. 2011; 1812:1272–1280. [PubMed: 21241798]
59. Lal B, Kapoor AK, Agrawal PK, Asthana OP, Srimal RC. Role of curcumin in idiopathic inflammatory orbital pseudotumours. *Phytother Res*. 2000; 14:443–447. [PubMed: 10960899]
60. Daugherty RL, Gottardi CJ. Phospho-regulation of Beta-catenin adhesion and signaling functions. *Physiology (Bethesda)*. 2007; 22:303–309. [PubMed: 17928543]
61. Li J, Sutter C, Parker D, Blauwkamp T, Fang M, Cadigan K. CBP/p300 are bimodal regulators of Wnt signaling. *EMBO J*. 2007; 26:2284–2294. [PubMed: 17410209]
62. Wang X, Lawson B, Brewer J, Zinszner H, Sanjay A, Mi L, Boorstein R, Kreibich G, Hendershot L, Ron D. Signals from the stressed endoplasmic reticulum induce C/EBP-homologous protein (CHOP/GADD153). *Mol Cell Biol*. 1996; 16:4273–4280. [PubMed: 8754828]
63. Maytin E, Ubada M, Lin J, Habener J. Stress-inducible transcription factor CHOP/gadd153 induces apoptosis in mammalian cells via p38 kinase-dependent and - independent mechanisms. *Exp Cell Res*. 2001; 267:193–204. [PubMed: 11426938]
64. Kopito R. Aggresomes, inclusion bodies and protein aggregation. *Trends Cell Biol*. 2000; 10:524–530. [PubMed: 11121744]
65. Harding H, Calton M, Urano F, Novoa I, Ron D. Transcriptional and translational control in the Mammalian unfolded protein response. *Annu Rev Cell Dev Biol*. 2002; 18:575–599. [PubMed: 12142265]
66. Wiertz E, Jones T, Sun L, Bogoy M, Geuze H, Ploegh H. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. *Cell*. 1996; 84:769–779. [PubMed: 8625414]
67. Nakatsukasa K, Brodsky J. The recognition and retrotranslocation of misfolded proteins from the endoplasmic reticulum. *Traffic*. 2008; 9:861–870. [PubMed: 18315532]
68. Ferri K, Kroemer G. Organelle-specific initiation of cell death pathways. *Nat Cell Biol*. 2001; 3:E255–E263. [PubMed: 11715037]
69. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner B, Yuan J. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. *Nature*. 2000; 403:98–103. [PubMed: 10638761]
70. Ubada M, Wang X, Zinszner H, Wu I, Habener J, Ron D. Stress-induced binding of the transcriptional factor CHOP to a novel DNA control element. *Mol Cell Biol*. 1996; 16:1479–1489. [PubMed: 8657121]
71. Ron D, Habener J. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. *Genes Dev*. 1992; 6:439–453. [PubMed: 1547942]
72. Matsumoto M, Minami M, Takeda K, Sakao Y, Akira S. Ectopic expression of CHOP (GADD153) induces apoptosis in M1 myeloblastic leukemia cells. *FEBS Lett*. 1996; 395:143–147. [PubMed: 8898082]

73. Oyadomari S, Koizumi A, Takeda K, Gotoh T, Akira S, Araki E, Mori M. Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. *J Clin Invest.* 2002; 109:525–532. [PubMed: 11854325]
74. Ohoka N, Hattori T, Kitagawa M, Onozaki K, Hayashi H. Critical and functional regulation of CHOP (C/EBP homologous protein) through the N-terminal portion. *J Biol Chem.* 2007; 282:35687–35694. [PubMed: 17872950]
75. Mangos S, Lam PY, Zhao A, Liu Y, Mudumana S, Vasilyev A, Liu A, Drummond IA. The ADPKD genes *pkd1a/b* and *pkd2* regulate extracellular matrix formation. *Dis Model Mech.* 2010; 3:354–365. [PubMed: 20335443]
76. Arslanova D, Yang T, Xu X, Wong ST, Augelli-Szafran CE, Xia W. Phenotypic analysis of images of zebrafish treated with Alzheimer's gamma-secretase inhibitors. *BMC Biotechnol.* 2010; 10:24. [PubMed: 20307292]

Figure 1. Schematic diagram of polycystin-1 structure and cleavages

Polycystin-1 is a massive polypeptide that is predicted to possess a large N terminal extracellular domain, eleven transmembrane segments (blue), and a short cytoplasmic C terminal tail. The N terminal domain includes sixteen copies of the Ig-like polycystin repeat (brown). Polycystin-1 undergoes several proteolytic cleavages (yellow arrows), including an autocatalytic cleavage at the G protein-coupled receptor proteolytic site (GPS) (green) that releases the N terminal domain, which remains non-covalently attached to the transmembrane domains. A cleavage in a cytosolic loop segment produces a fragment of ~100 kDa [47], and at least two cleavages release portions of the C terminus that enter the nucleus and influence transcriptional pathways [53, 55]

Figure 2. γ -Secretase mediated cleavage of polycystin-1 produces fragments that modulate the activity of the T-cell factor (TCF) and C/EBP homologous protein (CHOP) transcription factors Data from recent studies [57] indicate that γ -secretase activity participates in generating polycystin-1 cleavage fragments that influence the activity of the TCF and CHOP transcription factors, which modulate proliferation and apoptosis, respectively. Both TCF and CHOP require an interaction with the p300 transcriptional co-activator in order to regulate transcription of their target genes. The C terminal tail of polycystin-1 can interact with TCF and CHOP and prevent interactions between these transcription factors and p300. Thus, γ -secretase-dependent cleavage of polycystin-1 can generate a fragment or fragments that reduce the activities of the TCF and CHOP transcriptional pathways. This figure is reproduced with permission from [57].